552 related articles for article (PubMed ID: 23321417)
21. SLC7A5 act as a potential leukemic transformation target gene in myelodysplastic syndrome.
Ma Y; Song J; Chen B; Xu X; Lin G
Oncotarget; 2016 Feb; 7(6):6566-75. PubMed ID: 26657287
[TBL] [Abstract][Full Text] [Related]
22. Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome.
Dostalova Merkerova M; Krejcik Z; Votavova H; Belickova M; Vasikova A; Cermak J
Eur J Hum Genet; 2011 Mar; 19(3):313-9. PubMed ID: 21150891
[TBL] [Abstract][Full Text] [Related]
23. [Study on the transformation from myelodysplastic syndromes into acute leukemias].
Shi J; Shao Z; Liu H; Li K; Song L; Zhang Y; Zheng Y; Chen G; Chu Y; He H; Zhao M; He G; Feng B; Hao Y; Yang T; Yang C
Zhonghua Xue Ye Xue Za Zhi; 2001 Jul; 22(7):351-4. PubMed ID: 11877096
[TBL] [Abstract][Full Text] [Related]
24. Expression of the runt homology domain of RUNX1 disrupts homeostasis of hematopoietic stem cells and induces progression to myelodysplastic syndrome.
Matsuura S; Komeno Y; Stevenson KE; Biggs JR; Lam K; Tang T; Lo MC; Cong X; Yan M; Neuberg DS; Zhang DE
Blood; 2012 Nov; 120(19):4028-37. PubMed ID: 22919028
[TBL] [Abstract][Full Text] [Related]
25. Over-expression of miR-196b-5p is significantly associated with the progression of myelodysplastic syndrome.
Wen J; Huang Y; Li H; Zhang X; Cheng P; Deng D; Peng Z; Luo J; Zhao W; Lai Y; Liu Z
Int J Hematol; 2017 Jun; 105(6):777-783. PubMed ID: 28224273
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms underlying the heterogeneity of myelodysplastic syndromes.
Dussiau C; Fontenay M
Exp Hematol; 2018 Feb; 58():17-26. PubMed ID: 29175473
[TBL] [Abstract][Full Text] [Related]
27. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
[TBL] [Abstract][Full Text] [Related]
28. Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes.
Lin P; Luo Y; Zhu S; Maggio D; Yang H; Hu C; Wang J; Zhang H; Ren Y; Zhou X; Mei C; Ma L; Xu W; Ye L; Zhuang Z; Jin J; Tong H
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1037-1047. PubMed ID: 29549529
[TBL] [Abstract][Full Text] [Related]
29. Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia.
Thol F; Scherr M; Kirchner A; Shahswar R; Battmer K; Kade S; Chaturvedi A; Koenecke C; Stadler M; Platzbecker U; Thiede C; Schroeder T; Kobbe G; Bug G; Ottmann O; Hofmann WK; Kröger N; Fiedler W; Schlenk R; Döhner K; Döhner H; Krauter J; Eder M; Ganser A; Heuser M
Haematologica; 2015 Apr; 100(4):e122-4. PubMed ID: 25552704
[No Abstract] [Full Text] [Related]
30. Mechanisms of leukemic transformation in congenital neutropenia.
Link DC
Curr Opin Hematol; 2019 Jan; 26(1):34-40. PubMed ID: 30431463
[TBL] [Abstract][Full Text] [Related]
31. Cytogenetics in benzene-associated myelodysplastic syndromes and acute myeloid leukemia: new insights into a disease continuum.
Irons RD; Kerzic PJ
Ann N Y Acad Sci; 2014 Mar; 1310():84-8. PubMed ID: 24611724
[TBL] [Abstract][Full Text] [Related]
32. Myeloid cell differentiation arrest by miR-125b-1 in myelodysplastic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation.
Bousquet M; Quelen C; Rosati R; Mansat-De Mas V; La Starza R; Bastard C; Lippert E; Talmant P; Lafage-Pochitaloff M; Leroux D; Gervais C; Viguié F; Lai JL; Terre C; Beverlo B; Sambani C; Hagemeijer A; Marynen P; Delsol G; Dastugue N; Mecucci C; Brousset P
J Exp Med; 2008 Oct; 205(11):2499-506. PubMed ID: 18936236
[TBL] [Abstract][Full Text] [Related]
33. Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes.
Stevens BM; Khan N; D'Alessandro A; Nemkov T; Winters A; Jones CL; Zhang W; Pollyea DA; Jordan CT
Nat Commun; 2018 Sep; 9(1):3694. PubMed ID: 30209285
[TBL] [Abstract][Full Text] [Related]
34. Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy.
Dan C; Chi J; Wang L
Ann Med; 2015 May; 47(3):209-17. PubMed ID: 25861829
[TBL] [Abstract][Full Text] [Related]
35. Hematopoiesis-related microRNA expression in myelodysplastic syndromes.
Pons A; Nomdedeu B; Navarro A; Gaya A; Gel B; Diaz T; Valera S; Rozman M; Belkaid M; Montserrat E; Monzo M
Leuk Lymphoma; 2009 Nov; 50(11):1854-9. PubMed ID: 19883312
[TBL] [Abstract][Full Text] [Related]
36. Transcriptional down-regulation of the Wnt antagonist SFRP1 in haematopoietic cells of patients with different risk types of MDS.
Reins J; Mossner M; Neumann M; Platzbecker U; Schumann C; Thiel E; Hofmann WK
Leuk Res; 2010 Dec; 34(12):1610-6. PubMed ID: 20471677
[TBL] [Abstract][Full Text] [Related]
37. Heterogeneous patterns of CEBPalpha mutation status in the progression of myelodysplastic syndrome and chronic myelomonocytic leukemia to acute myelogenous leukemia.
Shih LY; Huang CF; Lin TL; Wu JH; Wang PN; Dunn P; Kuo MC; Tang TC
Clin Cancer Res; 2005 Mar; 11(5):1821-6. PubMed ID: 15756005
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of apoptosis by BCL2 prevents leukemic transformation of a murine myelodysplastic syndrome.
Slape CI; Saw J; Jowett JB; Aplan PD; Strasser A; Jane SM; Curtis DJ
Blood; 2012 Sep; 120(12):2475-83. PubMed ID: 22855610
[TBL] [Abstract][Full Text] [Related]
39. Clonal Hematopoiesis and therapy related MDS/AML.
Desai P; Roboz GJ
Best Pract Res Clin Haematol; 2019 Mar; 32(1):13-23. PubMed ID: 30927970
[TBL] [Abstract][Full Text] [Related]
40. The role of epigenetics in the regulation of apoptosis in myelodysplastic syndromes and acute myeloid leukemia.
Karlic H; Herrmann H; Varga F; Thaler R; Reitermaier R; Spitzer S; Ghanim V; Blatt K; Sperr WR; Valent P; Pfeilstöcker M
Crit Rev Oncol Hematol; 2014 Apr; 90(1):1-16. PubMed ID: 24183913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
